TAIPEI, Taiwan, R.O.C. -- June 5, 2009 -- InnoPharmax, Inc. announced that the Department of Health (DOH) has granted approvals for the Company's Abbreviated New Drug Applications (ANDA) for Immurin^® Soft Gelatin Capsule 100 mg (cyclosporine) and Gadoscan^® I.V. Injection (gadodiamide).
 

InnoPharmax's Immurin^® Soft Gelatin Capsule 100 mg is bioequivalent of Novartis' Sandimmun Neoral Soft Gelatin Cap 100 mg. It is indicated for prophylaxis of rejection in organ and bone marrow transplants, for the treatment of patients with severe psoriasis where the disease has not adequate or responded to conventional treatments, and for the treatment of severe rheumatoid arthritis who have failed or inadequate to substitution treatment.
 

InnoPharmax's Gadoscan^® I.V. Injection is generic of GE Healthcare's Omniscan Injection 0.5 mmol/ml, which is indicated for cranial/spinal and whole body magnetic resonance imaging (MRI). This is InnoPharmax's second approved contrast medium for MRI after the launch of Gadomni^® I.V. Injection in August 2007.